BRIEF-Vyne Therapeutics Provides Program Update On Oral BET Inhibitor VYN202

Reuters
02 Jul
BRIEF-Vyne <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Provides Program Update On Oral BET Inhibitor VYN202

July 2 (Reuters) - Vyne Therapeutics Inc VYNE.O:

  • VYNE THERAPEUTICS PROVIDES PROGRAM UPDATE ON ORAL BET INHIBITOR VYN202

  • VYNE THERAPEUTICS INC - FDA LIFTS CLINICAL HOLD FOR FEMALE PATIENTS ON 0.25 MG AND 0.5 MG DOSES

  • VYNE THERAPEUTICS INC - 12-WEEK TOXICOLOGY STUDY IN DOGS REQUIRED TO RESUME TRIAL IN MALES

  • VYNE THERAPEUTICS INC - TO STOP ENROLLING PATIENTS IN PHASE 1B PSORIASIS STUDY

  • VYNE THERAPEUTICS INC - UNBLINDS CLINICAL DATA FROM ENROLLED SUBJECTS IN STUDY

Source text: ID:nGNX4z5k55

Further company coverage: VYNE.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10